Inflammatory regulatory mechanisms and targeted therapy of antineutrophil cytoplasmic antibodies in atherosclerosis (Review)
International Journal of Molecular Medicine · 22.10.2026 · 58 (6) · 1-22
DOI: 10.3892/ijmm.2026.6023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 22.10.2026. Verfasst von Jingjing Cui und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Bethune International Peace Hospital, Shijiazhuang, Hebei 050082, P.R. China. Hauptthemen laut MEDLINE: Atherosclerosis, Antibodies, Antineutrophil Cytoplasmic, Inflammation, Molecular Targeted Therapy. Die Arbeit nennt 178 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Atherosclerosis is the core pathological basis of cardiocerebrovascular diseases, and inflammatory response runs through the course of its occurrence, progression, and adverse events. Antineutrophil cytoplasmic antibodies (ANCAs) are autoantibodies targeting the lysosomal components in the cytoplasm of neutrophils and monocytes, and their association with atherosclerosis and pathogenic effects have become a research hotspot in cardiovascular medicine. The present review systematically examined the core molecular mechanisms of ANCA‑mediated atherosclerosis, focusing on analyzing the pro‑atherogenic effects of ANCAs through the regulation of monocyte dysfunction, induction of the formation of neutrophil extracellular traps, and activation of the synergistic complement‑platelet pathway, and clarified the subtype‑specific pathogenic pathways mediated by myeloperoxidase‑ANCAs and proteinase 3‑ANCAs. The present review also summarized the clinical evidence linking ANCA positivity to the risk of atherosclerosis, plaque characteristics, and clinical outcomes and explores the precise intervention strategies for targeting ANCA‑related pathways in atherosclerosis. Finally, it highlighted the limitations of current research and future directions to provide a theoretical reference and novel insights for the risk stratification of populations at high risk of atherosclerosis and the precise management of residual inflammatory risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Bethune International Peace Hospital, Shijiazhuang, Hebei 050082, P.R. China.
- Department of Clinical Laboratory, Baoding No. 1 Central Hospital, Baoding, Hebei 071000, P.R. China.
- Teaching and Research Section of Human Body and Life, Non‑Commissioned Officer School, Army Medical University, Shijiazhuang, Hebei 050081, P.R. China.
Zitieren
APA
Cui, J., Cui, Q., Dou, J., Li, X., Chang, W., Shi, L., & An, L. (2026). Inflammatory regulatory mechanisms and targeted therapy of antineutrophil cytoplasmic antibodies in atherosclerosis (Review). International Journal of Molecular Medicine, 58(6), 1-22. https://doi.org/10.3892/ijmm.2026.6023
Vancouver
Cui J, Cui Q, Dou J, Li X, Chang W, Shi L, et al. Inflammatory regulatory mechanisms and targeted therapy of antineutrophil cytoplasmic antibodies in atherosclerosis (Review). International Journal of Molecular Medicine. 2026;58(6):1-22. doi:10.3892/ijmm.2026.6023
BibTeX
@article{Cui2026,
author = {Cui, Jingjing and Cui, Qi and Dou, Jinying and Li, Xiaoyan and Chang, Wenlong and Shi, Lanchun and An, Liyun},
title = {Inflammatory regulatory mechanisms and targeted therapy of antineutrophil cytoplasmic antibodies in atherosclerosis (Review)},
journal = {International Journal of Molecular Medicine},
year = {2026},
volume = {58},
number = {6},
pages = {1--22},
doi = {10.3892/ijmm.2026.6023}
}
EUVIMED